Table 4 Overall survival of lung adenocarcinoma patients according to the analysed variables

Age (years)

≤65

20.109 (1.762); 15.656–23.561

10.00 (0.972)

8.095–11.905

> 65

19.331 (1.711);

15.977–22.684

10.00 (3.232)

3.664–16.336

Sex

Male

18.443 (1529); 15.445–21.440

9 (1.002);

7.037–10.963

Female

22.049 (2.049);

18.044–26.055

17 (3972);

9.215–24.785

Smoking status

Yes

17.4 (1.935)

13.607–21.193

8 (1224)

5.600–10.400

No

15.116

8.760–21.471

16 (10.797)

0–37.163

ECOG

0

25.916 (2.468)

21.079–30.754

23 (3.910)

15.336–30.664

1

12.172 (2.073)

8.109–16.235

7 (1.113)

4.819–9.181

2

10.882 (3.096)

4.815–16.950

7 (1.543)

3.975–10.025

3

4.750 (2.169)

0.498–9.002

2 (0.685)

0.658–3.342

4

2.36 (1.073)

0.534–4.739

2 (0.591)

0.842–3.158

TNM stage*

I + II

39.355 (2.654)

34.154–44.556

39 (7.649)

24.009–53.991

III

25.660 (3.171)

19.444–31.876

23 (3.312)

16.08–29.492

IV

13.861 (1.355)

7 (0.762)

Tumor size

T1

32.709 (4702)

23.494–41.924

T2

28.521 (2.419)

23.779–33.262

23 (3.512)

16.116–29.884

T3

19.520 (2.272)

15.068–23.973

10 (2.371)

2.371–5.353

T4

9.240 (1.201)

6.886–11.595

5 (0,625)

3.774–6.226

Lymph node

Negative

36.468 (2.402)

31.761–41.175

45 (9468)

26.443–63.557

Positive

12.137–17.275

7 (0,739)

5.552–8.448

Metastasis

No

33.370 (2.201)

29.057–37.683

32 (5,4)

21.416–42.84

Yes

13.819 (1.348)

11.178–16.461

7 (0,734)

5.561–8.439

ERCC1

≤ 0.1

30.793 (2.543)

25.810–35.777

25 (4.594)

15.996–34.004

>  0.1

5.951 (0.696)

4.586–7.316

5 (0.441)

4.135–5.865

TNM IV/C**

≤ 0.1

24.719 (2.034)

20.732–28.705

24 (3.607)

16.931–31.069

>  0.1

5.511 (0.564)

4.404–6.617

5 (0.295)

4.421–5.572

TNM I-III/ C + S or R**

≤ 0.1

45.727 (4.025)

37.838–53.616

>  0.1

11.400 (4.614)

2.356–20.444

8 (4.382)

0–18.588